Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05099289
Other study ID # DOC-10154
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 17, 2021
Est. completion date March 31, 2022

Study information

Verified date July 2022
Source AtaCor Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PASS PULL EV-ICD Study is a prospective, multi-center, single-arm study without concurrent or historical controls. This initial concept feasibility study is primarily intended to demonstrate that the EV-ICD Lead can be safely positioned within the anterior mediastinum as intended using the AtaCor delivery system. The study will secondarily characterize the ability for the EV-ICD Lead to facilitate VF sensing and defibrillation.


Description:

The primary objective of the study is to demonstrate that the AtaCor EV-ICD Lead can be safely positioned within the anterior mediastinum as intended using the EV-ICD Dilator and EV-ICD Delivery Tool. The study will secondarily characterize the ability for the EV-ICD Lead to facilitate VF sensing and defibrillation. Up to 3 Investigational Sites will participate with up to 65 subjects enrolled in the study. Patients undergoing de novo or replacement ICD procedure will be eligible for participation. Study participation requires acute evaluation of the EV-ICD Lead during the index procedure. Echocardiography will be used to evaluate any new or worsening pericardial effusions. A follow-up visit will occur 7-10 days post-removal via phone, video call, or in-person. Participation will end after completion of the 7-10 days post-removal visit. The Study is expected to last up to 3 months for enrollment.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date March 31, 2022
Est. primary completion date February 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. At least 18 years old 2. Indicated for de novo or replacement ICD procedure Exclusion criteria 1. NYHA IV functional class 2. BMI = 35 kg/m2 3. Inotropic therapy in past 180 days 4. Subjects with a hemodynamically unstable intrinsic heart rate that requires continual ventricular pacing 5. Presence or planned use of subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads 6. Subjects on anticoagulation/antiplatelet therapy that cannot be temporarily discontinued for the procedure 7. Logistical or safety related circumstances that may prevent data collection or follow-up 8. Participation in any concurrent clinical study without prior written approval from the Sponsor 9. Inability to give an informed consent to participate in the Study Known prior history for any of the following: 10. Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum for the EV-ICD Dilator, EV-ICD Delivery Tool and EV-ICD Lead as assessed from available CT or Echocardiography. 11. Uncontrolled paroxysmal, persistent or permanent atrial fibrillation 12. Median or partial sternotomy 13. Surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium 14. Significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) 15. Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the EV-ICD Lead insertion procedure 16. Pericardial disease, pericarditis and mediastinitis 17. Medical treatments, surgeries or conditions that increase the potential for pericardial adhesions 18. FEV1 < 1.0 Liter 19. Surgically corrected congenital heart disease (not including catheter-based procedures) 20. Allergies to the device materials as listed in the Instructions for Use (IFU)

Study Design


Intervention

Device:
AtaCor EV-ICD Lead
Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.

Locations

Country Name City State
Paraguay Sanatorio Italiano Asunción

Sponsors (1)

Lead Sponsor Collaborator
AtaCor Medical, Inc.

Country where clinical trial is conducted

Paraguay, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of SADEs Incidence of Serious Adverse Device Effects (SADEs) Up to 10 days post-procedure
Primary Rate of Insertion Success Defined as the ability to deploy the lead in a position within the mediastinum that is suitable for defibrillation testing and does not result in one (1) or more SADEs Procedure
Secondary Functionality - Lowest Defibrillation Conversion Energy Lowest Defibrillation Conversion Energy (J) Procedure
Secondary Observational: Incidence of ADEs Incidence of Adverse Device Effects (ADEs), Overall and Individual Up to 10 days post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01791543 - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT04642963 - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A